muscular disease: Acquired, familial, and congenital disorders of skeletal muscle and smooth muscle.
Muscle wasting and atrophy, not elsewhere classified
DOID EFO Endpoint Browser PheWeb
M13_MUSCLEATROPH
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
---|---|
Phenotype data |
473681 |
1. Apply sex-specific ruleNone |
473681 |
2. Check conditionsNone |
473681 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
194 |
4. Check minimum number of eventsNone |
194 |
5. Include endpointsNone |
194 |
6. Filter based on genotype QC (FinnGen only) |
189 |
Control definitions (FinnGen only)
Extra metadata
Similar endpoints
↥List of similar endpoints to Muscle wasting and atrophy, not elsewhere classified based on the number of shared cases.
Similar with more cases:
- Disorders of muscles
- Soft tissue disorders
- Diseases of the musculoskeletal system and connective tissue
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
Key figures
All | Female | Male | |
---|---|---|---|
Number of individuals | |||
Whole population | 1539 | 650 | 867 |
Only index persons | 1277 | 562 | 715 |
Unadjusted period prevalence (%) | |||
Whole population | 0.02 | 0.02 | 0.02 |
Only index persons | 0.02 | 0.02 | 0.03 |
Median age at first event (years) | |||
Whole population | 58.20 | 59.33 | 57.32 |
Only index persons | 57.86 | 58.68 | 57.22 |
-FinnGen-
Key figures
All | Female | Male | |
---|---|---|---|
Number of individuals | 189 | 88 | 101 |
Unadjusted period prevalence (%) | 0.04 | 0.03 | 0.05 |
Median age at first event (years) | 57.51 | 54.14 | 60.44 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
Mortality – FinRegistry
↥Association
Association between endpoint M13_MUSCLEATROPH and mortality.
Females
Parameter | HR [95% CI] | p-value |
---|---|---|
M13_MUSCLEATROPH | 2.0 [1.43, 2.8] | < 0.001 |
Birth year | 0.994 [0.99, 1.0] | 0.168 |
During the follow-up period (1.1.1998 — 31.12.2019), 100 out of 431 females with M13_MUSCLEATROPH died.
Males
Parameter | HR [95% CI] | p-value |
---|---|---|
M13_MUSCLEATROPH | 2.175 [1.62, 2.92] | < 0.001 |
Birth year | 0.988 [0.98, 1.0] | 0.012 |
During the follow-up period (1.1.1998 — 31.12.2019), 165 out of 582 males with M13_MUSCLEATROPH died.
Mortality risk
Mortality risk for people of age
years, who have M13_MUSCLEATROPH.N-year risk | Females | Males |
---|---|---|
1 | 0.222% | 0.409% |
5 | 1.237% | 2.655% |
10 | 3.025% | 6.217% |
15 | 5.429% | 11.554% |
20 | 9.286% | 19.826% |
Relationships between endpoints
↥Index endpoint: M13_MUSCLEATROPH – Muscle wasting and atrophy, not elsewhere classified
GWS hits: -